Showing 6621-6630 of 10001 results for "".
- Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2018 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/calling-all-students-ortho-dermatologics-now-accepting-applications-for-the-2018-aspire-higher-scholarship-program/2457855/Ortho Dermatologics is accepting applications for the 2018 Aspire Higher scholarship program for students who have been affected by dermatologic conditions. Through the program, nine students will receive a scholarship of $10,000. The
- Early Botox Improves Final Appearance in 'Split-Scar' Studyhttps://practicaldermatology.com/news/early-botox-treatment-improves-final-appearance-in-split-scar-study/2457856/Early injections of botulinum toxin A can improve the final appearance of surgical scars, according to a study in the March issue of Plastic
- Dermira Presents Positive Data on Treating Pediatric Patients with Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermira-presents-positive-data-on-treating-pediatric-patients-with-axillary-hyperhidrosis/2457873/Dermira, Inc. presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program showing that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediat
- Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-presents-analysis-of-siliq-phase-3-data-on-disease-related-anxiety-and-depression-in-patients-with-psoriasis/2457875/Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities associated with psoriasis, such as anxiety and depression. These findings were presented for the
- Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meetinghttps://practicaldermatology.com/news/lilly-new-taltz-data-and-pipeline-update-to-be-presented-at-aad-annual-meeting/2457885/Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include eight abstracts for Tal
- FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-jemdel-plaque-psoriasis-treatment/2457889/The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved, Jemdel will be the first high-potency topical steroid treatment for plaque psoriasis with dosin
- NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastaseshttps://practicaldermatology.com/news/nanology-enrolls-first-patient-in-clinical-trial-for-cutaneous-metastases/2457887/NanOlogy™, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, has enrolled the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose esca
- South Beach Symposium to Kick Off March 1https://practicaldermatology.com/news/south-beach-symposium-to-kick-off-march-1/2457895/Now celebrating its 16th year, the 2018 South Beach Symposium (SBS) will feature live demonstration workshops of minimally invasive aesthetic treatments with injectables and devices providing attendees with new skills and techniques th
- FDA Approves Cosentyx Label Update to Include Scalp Psoriasishttps://practicaldermatology.com/news/fda-approves-cosentyx-label-update-to-include-scalp-psoriasis/2457896/The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label includes Cosentyx data in moderate to severe scalp psoriasis—one of the difficult-to-treat for
- eRelevance Adds Two to Executive Leadership Teamhttps://practicaldermatology.com/news/erelevance-adds-two-to-executive-leadership-team/2457901/eRelevance has added two new names to its executive leadership team. Rafael Landestoy is now vice president of business development and Travis Skidmore is vice president of client success and retention. Mr. Landestoy will lead eRelevance&nbs